Liraglutide

A GLP-1 receptor agonist approved for type 2 diabetes and, at higher dose, for weight management.

What research shows

Liraglutide is a licensed medicine with substantial randomized evidence: dedicated obesity trials at the higher dose, and pooled analyses showing reduced cardiovascular events across the GLP-1 class. This is what a well-evidenced compound looks like, and the contrast with most of this library is the point.

Evidence strength

Highest evidence grade among the graded claims: A. Grades reflect study strength, not benefit.

Safety context

See the safety section. Absence of a flag is not evidence of safety.

No endorsement

A grade reflects evidence strength, not a recommendation to use this compound; a strong grade can attach to a harmful effect.